secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001193125-25-152652
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics enters $275M loan agreement with Hercules Capital; $100M funded immediately
--------------------------------------------------------------------------------

- Initial tranche of $100M funded on June 27, 2025; additional tranches up to $175M available upon milestones and lender discretion.
- Interest rate of WSJ Prime + 2.45% (floor 7.50%); maturity July 1, 2030; interest-only until July 1, 2028, extendable.
- First-priority security interest on substantially all assets including IP; covenants include minimum cash and minimum net product revenue post-approval of DYNE-101 or DYNE-251.
- Prepayment penalty ranges from 0.75% to 2.0% of prepaid amount; end-of-term charge of 5.5%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525152652/0001193125-25-152652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525152652/d80696d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-152652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer